Showing 15 posts of 16 posts found.

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

July 24, 2023
Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …


United Therapeutics buys Arena’s hypertension drug ralinepag in deal worth $1.2 billion

November 16, 2018
Medical Communications Arena, PAH, United Therapeutics, deal sales, hypertension

US pharma firm United Therapeutics has agreed to by Arena Pharmaceuticals experimental pulmonary arterial hypertension (PAH) drug ralinepag in a …


Kitov’s combo gets FDA approval in osteoarthritis and hypertension

June 1, 2018
Medical Communications, Sales and Marketing Consensi, FDA, Kitov, US, hypertension, osteoarthritis, pharma

Israeli biopharmaceutical firm is celebrating the approval in the US of Consensi, a combo of the calcium channel blocker amlodipine …

Glenmark greenlighted to market hypertension generic in US

May 30, 2017
Manufacturing and Production, Sales and Marketing FDA, Glenmark, generic, hypertension

Glenmark Pharmaceuticals has revealed it has been awarded final approval by the FDA to market hypertension treatment nebivolol, a generic …


FDA approves Allergan hypertension fixed-dose combo, Byvalson

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, FDA, US, angiotensin ii, approval, beta blocker, byvalson, hypertension, nebivolol, valsartan

Allergan has announced that the US Food and Drug Administration (FDA) has approved its fixed-dose combination, Byvalson (nebivolol and valsartan), …


Actelion granted EU approval for hypertension treatment

May 17, 2016
Manufacturing and Production, Sales and Marketing Actelion, Uptravi, eu approval, hypertension

Actelion Pharmaceuticals has received marketing authorisation from the European Commission for Uptravi (selexipag) for the long-term treatment of patients with …


Mylan launches new dosages of generic of Novartis hypertension drug in US

April 11, 2016
Manufacturing and Production Mylan, Novartis, generic, high blood pressure, hypertension

Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor …

bayer image

Bayer pill gains FDA approval despite shutdown

October 9, 2013
Sales and Marketing Bayer, FDA, adempas, hypertension

In the midst of the US shutdown of government agencies the FDA has managed to approve Bayer’s Adempas for patients …

Takeda’s blood pressure treatment Edarbi approved

December 9, 2011
Sales and Marketing Diovan, Eisai, cardiovascular, high blood pressure, hypertension

Takeda’s new hypertension treatment Edarbi has been approved in Europe.Edarbi (azilsartan medoxomil) is a new once-daily angiotensin receptor blocker (ARB) …

BMS and Sanofi recall 64 million Avalide tablets

January 18, 2011
Manufacturing and Production Avalide, Avapro, Bristol-Myers Squibb, GMP, Good Manufacturing Practice, Sanofi-Aventis, hypertension, irbesartan

Bristol-Myers Squibb and Sanofi-Aventis have started another massive recall of their antihypertensive product Avalide because a manufacturing defect could affect …

New global ‘polypill’ trials start

May 17, 2010
Research and Development Dr Reddy, hypertension, polypill, statin

New trials of a daily polypill – combining aspirin, a statin and two blood pressure lowering medicines – are underway …

Tekturna fails to show heart attack benefit

March 17, 2010
Research and Development Diovan, Novartis, Tekturna, hypertension

Novartis’ hypertension treatment Tekturna has failed to show it helps patients recover from a heart attack when added to standard …

Conventional hypertension prescribing ‘should be reconsidered’

March 16, 2010
NICE, hypertension

New findings throwing doubt on conventional wisdom about high blood pressure may have implications for NICE’s advice on hypertension. Published …

Triple approval for Novartis in Japan

January 20, 2010
Sales and Marketing Afinitor, Asia, Exforge, Galvus, Japan, Novartis, hypertension

Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced …

European approval for 3-in-1 version of Exforge

October 23, 2009
Sales and Marketing Diovan, Exforge, Novartis, cv, hypertension

European regulators have approved an expanded version of Novartis’ high blood pressure treatment Exforge.Exforge was first approved in Europe in …

Latest content